Global Proton Pump Inhibitors (PPIs) Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Proton Pump Inhibitors (PPIs) Market Research Report 2024
Proton-pump inhibitors (PPIs) are a group of medications whose main action is a pronounced and long-lasting reduction of stomach acid production.
Proton pump inhibitors (PPIs) reduce the production of acid by blocking the enzyme in the wall of the stomach that produces acid. Acid is necessary for the formation of most ulcers in the esophagus, stomach, and duodenum, and the reduction of acid with PPIs prevents ulcers and allows any ulcers that exist in the esophagus, stomach, and duodenum to heal.
PPIs are among the most widely sold medications in the world. The class of proton-pump inhibitor medications is on the World Health Organization's List of Essential Medicines.
Medically used proton pump inhibitorsOmeprazole, Lansoprazole, Dexlansoprazole, Esomeprazole, Pantoprazole, Rabeprazole.
According to Mr Accuracy reports’s new survey, global Proton Pump Inhibitors (PPIs) market is projected to reach US$ 15000 million in 2034, increasing from US$ 12190 million in 2022, with the CAGR of 2.9% during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Proton Pump Inhibitors (PPIs) market research.
Global Proton Pump Inhibitors key players include AstraZeneca, Takeda, etc. Global top two manufacturers hold a share over 15%.
North America is the largest market, with a share about 30%, followed by Asia-Pacific, and Europe, having a share about 52 per୩
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Proton Pump Inhibitors (PPIs) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
AstraZeneca
Pfizer
Janssen
Eisai
Eli Lilly
Cadila Pharmaceuticals
Santarus
Wyeth
Changzhou Siyao Pharmaceuticals
Yangzhou Pharmaceutical
Segment by Type
Pantoprazole
Omeprazole
Lansoprazole
Esomeprazole
Rabeprazole
Others
Hospitals
Clinics
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Proton Pump Inhibitors (PPIs) report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Proton pump inhibitors (PPIs) reduce the production of acid by blocking the enzyme in the wall of the stomach that produces acid. Acid is necessary for the formation of most ulcers in the esophagus, stomach, and duodenum, and the reduction of acid with PPIs prevents ulcers and allows any ulcers that exist in the esophagus, stomach, and duodenum to heal.
PPIs are among the most widely sold medications in the world. The class of proton-pump inhibitor medications is on the World Health Organization's List of Essential Medicines.
Medically used proton pump inhibitorsOmeprazole, Lansoprazole, Dexlansoprazole, Esomeprazole, Pantoprazole, Rabeprazole.
According to Mr Accuracy reports’s new survey, global Proton Pump Inhibitors (PPIs) market is projected to reach US$ 15000 million in 2034, increasing from US$ 12190 million in 2022, with the CAGR of 2.9% during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Proton Pump Inhibitors (PPIs) market research.
Global Proton Pump Inhibitors key players include AstraZeneca, Takeda, etc. Global top two manufacturers hold a share over 15%.
North America is the largest market, with a share about 30%, followed by Asia-Pacific, and Europe, having a share about 52 per୩
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Proton Pump Inhibitors (PPIs) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
AstraZeneca
Pfizer
Janssen
Eisai
Eli Lilly
Cadila Pharmaceuticals
Santarus
Wyeth
Changzhou Siyao Pharmaceuticals
Yangzhou Pharmaceutical
Segment by Type
Pantoprazole
Omeprazole
Lansoprazole
Esomeprazole
Rabeprazole
Others
Segment by Application
Hospitals
Clinics
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Proton Pump Inhibitors (PPIs) report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices